APA (7th ed.) Citation

Farraye, F. A., Qazi, T., Kotze, P. G., Moore, G. T., Mundayat, R., Lawendy, N., . . . Judd, D. T. (2021). The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme. Alimentary Pharmacology & Therapeutics, 54(4), 429. https://doi.org/10.1111/apt.16439

Chicago Style (17th ed.) Citation

Farraye, Francis A., Taha Qazi, Paulo G. Kotze, Gregory T. Moore, Rajiv Mundayat, Nervin Lawendy, Puza P. Sharma, and Donna T. Judd. "The Impact of Body Mass Index on Efficacy and Safety in the Tofacitinib OCTAVE Ulcerative Colitis Clinical Programme." Alimentary Pharmacology & Therapeutics 54, no. 4 (2021): 429. https://doi.org/10.1111/apt.16439.

MLA (9th ed.) Citation

Farraye, Francis A., et al. "The Impact of Body Mass Index on Efficacy and Safety in the Tofacitinib OCTAVE Ulcerative Colitis Clinical Programme." Alimentary Pharmacology & Therapeutics, vol. 54, no. 4, 2021, p. 429, https://doi.org/10.1111/apt.16439.